🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

1/ Delighted to share our work on FH-deficient RCC Clinical Cancer Research Led by former fellow, now attending Jack Gleeson clincancerres.aacrjournals.org/content/27/10/…

2/ FH-RCC is a rare type of kidney cancer associated with germline FH mutations. The prevalence of FH-RCC in pts without germline mutations and response to standard RCC systemic therapy is not well described. Recent review by Aikseng Ooi: sciencedirect.com/science/articl…

3/ In 32 pts with FH-RCC, 16% had biallellic somatic FH loss and no germline FH mutation. No molecular/clinical differences were found (although small numbers). Compared to clear cell RCC, FH-RCC had lower mutation count but higher fraction of genome altered.

4/ On retrospective evaluation, responses were seen with mTOR/VEGF combination (ORR 44%), VEGF monotherapy (ORR 20%), but not with checkpoint inhibitor monotherapy (n=8, ORR 0%).

5/ Remaining questions: Response to VEGF/IO combinations? 1/1 patient in our cohort had a PR with lenvatinib+pembrolizumab. In ph2 cabozantinib+nivolumab trial presented by Chung-Han Lee 李宗翰, MD/PhD at #ASCO21- 4 of 5 RCC with FH mutations had a PR meetinglibrary.asco.org/record/195580/…

6/ Many thanks to Robert Motzer MD, @unclassified1, Ines Nikolovski, Sujata Patil, Andrea Knezevic, Martin Voss, Dr. Darren Feldman, ari hakimi, and Ed Reznik, and to all patients involved.

Take an early look at the front page of The Wall Street Journal wsj.com

When folks think about highly vaccinated places in America They think Vermont or CT or MA Those places are good But not the most vaccinated place in America So who's #1? Puerto Rico! But PR has gotten way too little attention Its worth reflecting on how they did it Thread

Go Blue!

Excited to share our report from a Phase II trial of neoadjuvant Nivolumab in high risk localized #kidneycancer published today in European Urology authors.elsevier.com/c/1ebrS14kplrE…

Cabozantinib plus Nivolumab shows a 48% objective response rate in a phase II study in non-clear cell RCC. Journal of Clinical Oncology Robert Motzer MD Memorial Sloan Kettering Cancer Center ascopubs.org/doi/abs/10.120…

Cabozantinib + Nivolumab in non-clear cell #RenalCellCarcinoma 🗒️ Phase II trial 🧑🏽‍🤝‍🧑🏽 n=47  🙌 Response rate 48% 🤩 Responses seen in 10/12 pts w/ either NF2 or FH mutations #JCO #kcsm @chunghanlee3 fal.cn/3nsdp

🔔TODAY! at 7PM ET!!🔔 Join Drs. Todd 〽️ Morgan, MD, Marie Carlo, Elisabeth Heath, & Brian Helfand for this FREE live virtual CME course that will address the latest developments in advanced #ProstateCancer disease‼️ #UroSoMe You won't want to miss this!➡️ow.ly/pQat50IBlAc

Experts review a clinical scenario of intermediate- and poor-risk renal cell carcinoma that is managed with ipilimumab-nivolumab and nivolumab maintenance. Robert Motzer MD Marie Carlo Chung-Han Lee 李宗翰, MD/PhD Memorial Sloan Kettering Cancer Center #kcsm ow.ly/QIE350IIOB7

This was a pleasure to write with Cantley Lab and we hope this Review will be useful for oncologists, translational scientists, and patients. Thanks to David Killock and the team NatureRevClinOncol for the outstanding editorial process!

Negative study for MEDI0680 + Durvalumab vs. Nivolumab in RCC, but really interesting to see decrease in ctDNA at 4 weeks was associated with improved PFS. Look forward to seeing whether this is replicated in other trials. Martin Voss doi.org/10.1158/1078-0…

Retrospective study showing benefit of TKI/ICI in FH-deficient RCC in European Urology europeanurology.com/article/S0302-… Would love to see a larger prospective study to validate our initial finding that cabo/nivo had 5/6 objective responses for these patients ascopubs.org/doi/full/10.12… Journal of Clinical Oncology

So excited to share our latest work in Cancer Discovery doi.org/10.1158/2159-8…, led by two incredible folks Lynda Vuong and UrologyMSK fellow Phillip Rappold in collaboration with Novartis Cancer. We are also thrilled to introduce a transplantable, immunocompetent #kidneycancer mouse model!

Congrats to Hong Truong and Kelsey Breen for taking the lead in this amazing effort! Will help us better counsel PC pts who come in with a tumor profiling report, asking how likely it is they have an inherited cancer syndrome.

Progression-free Survival After Second Line of Therapy for Metastatic Clear Cell Renal Cell Carcinoma in Patients Treated with First-line Immunotherapy Combinations buff.ly/3Uf2NoX Chung-Han Lee 李宗翰, MD/PhD Ritesh Kotecha David H Aggen, MD PhD Neil Shah Dr. Darren Feldman Robert Motzer MD